Financial Profile
  
   
UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 31ST MARCH, 2002
  
Rs in millions
Quater Ended
Year Ended
31.03.2002
31.03.2001
31.03.2002
31.03.2001
(Audited)
1
Net Sales
3856.2
2605.6
13868.0
10475.1
2
Other Income
107.4
138.6
440.5
386.1
3
Total Expenditure
    
a) (Increase) / decrease in Stock-in -trade
(444.0)
62.4
(810.9)
(375.8)
   
 
b) Consumption of  Materials
2002.4
1280.1
6939.1
5236.6
 
c) Staff Cost
178.4
122.9
640.4
499.0
d) Excise Duty
407.3
139.2
1091.6
808.3
e) Other Expenditure
910.9
652.6
3196.4
2152.8
4
Interest
5.0
0.9
20.0
8.3
5
Depreciation
71.5
32.5
215.0
156.3
6
Profit (+) / Loss (-) before Tax     (1+2-3-4-5)
832.1
453.6
3016.9
2375.7
7
Provision for Taxation
*215.0
110.0
*725.0
585.0
8
Net Profit (+) / Loss (-) (6-7)
617.1
343.6
2291.9
1790.7
9
Paid-up Equity Share Capital
599.7
599.7
599.7
599.7
10
Reserves excluding Revaluation Reserves  (as per balance-sheet of previous accounting year)
6540.5
11
Earning per Share
** Not Annualised
**10.29
**5.73
38.21
29.86
12

Aggregate of
Non-Promoter Shareholding

- Number of Shares
36715294
36505209
36715294
36505209

- Percentage of Shareholding
61.22
60.87
61.22
60.87
Notes:
1
* Provision for tax includes deferred taxation
2
The Company is exclusively in the pharmaceutical business segment
3
The above results were taken on record at the meeting of the Board of Directors held on 29th April, 2002.

 

Mumbai
29th April, 2002.

By order of the Board
For CIPLA LIMITED



M. K. Hamied
Joint Managing Director